|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
Trading: SELL @ $3.37
Signal Strength: WEAK
Indicator MUST BE USED in additional to another technical indicator to confirmation for trading entry. Indicator can be applied to the short term timeframe but is only able to give and indication of the strength of the buyers versus sellers at the market close. This bar analysis can provide guidance on the daily battle between sellers and buyers from the companies recent trading.
Opthea (ASX:OPT) sellers are keener than buyers and are driving the price down. There has been 3 consecutive days of price decline for OPT adding strength to a downtrend in the first timeframe. The biggest downward movement this month has been -3.7 & the greatest daily negative change this year has been -3.7. The longest consecutive downswing rally over the last 12 months has been 7 days giving a total rally downward movement of -54.4%. This quarter, the largest downswing rally has been 3 days giving a total rally downward movement of -8.3%. The loss ratio for price rise in the first timeframe for the last 12 months is 0x giving a total win/loss ratio of 0.8x. Over the last month the average daily downward movement has been -1.600000%
The only price most market participants look at is the closing price in relation to the previous day’s close. As such the position of the close has the ability to highlight recent performance and indirectly the keenness of traders.
[Calculations] Close Today Versus Close Yesterday (CTCY):
1) [Close] > [Close Yesterday] = Buyers keener than sellers;
2) [Close] < [Close Yesterday] = Sellers keener than buyers;
3) [Close] = [Close Yesterday] = Neither are keener
PROFILE: Opthea (OPT.AX)
Stock Exchange: ASX
Ticker Codes: | OPT.AX | ASX:OPT |
Opthea Limited develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) C and D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3, which is in Phase 1/2A clinical trial for the treatment of back of the eye diseases, such as wet age-related macular degeneration that is the cause of blindness in elderly and diabetic populations. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited is based in South Yarra, Australia.
|XPJ ASX 200 Property Trusts||1662.8||0||0||-1||BEARISH|
|CGF Challenger Financial Services||8.55||-0.1||2,440,735||-1||BEARISH|
|MCY Mighty River Power||5.02||-0.2||1,400||-1||BEARISH|
|XTJ ASX 200 Telecomms||1369.9||-0.2||0||-1||BEARISH|
|ASX Australian Stock Exchange||83.83||-0.2||190,063||-1||BEARISH|
|XXJ ASX 200 Fin-X-Prop||6926.1||-0.3||0||-1||BEARISH|
|XFJ ASX 200 Financials||6209.9||-0.3||0||-1||BEARISH|